Key result
Loop diuretic withdrawal does not significantly increase congestion risk compared to continuation in stable HF.
Why the study?
Prolonged loop diuretic use in heart failure may contribute to poor outcomes and adverse events, yet evidence supporting safe withdrawal and appropriate patient selection among ambulatory HF patients with T2DM remains limited.
Does short-term withdrawal of loop diuretics increase the risk of clinical or subclinical congestion over 4 weeks compared to loop diuretic continuation in clinically euvolemic ambulatory heart failure patients with type 2 diabetes mellitus?
RCT (n=60)
Open-label (with blinded central offline ultrasound image analysis)
Stratified 2-by-2 block randomization
No
Does short-term withdrawal of loop diuretics increase the risk of clinical or subclinical congestion over 4 weeks compared to loop diuretic continuation in clinically euvolemic ambulatory heart failure patients with type 2 diabetes mellitus?
Short-term withdrawal of loop diuretics over 4 weeks in clinically euvolemic, well-optimized ambulatory heart failure patients with type 2 diabetes was feasible without a significant increase in overall clinical or subclinical congestion, while baseline NT-proBNP independently predicted congestion development.
Answers are grounded in this paper and cite their sources.
Short-term withdrawal may be feasible in euvolemic HF with T2D; hypothesis-generating pilot data requiring larger trials before practice change.
Introduction: Loop diuretics (LD) are central in the management of heart failure (HF) congestion. However, prolonged use may contribute to poor outcomes and adverse events. Evidence supporting safe withdrawal of LD and appropriate patient selection among ambulatory HF patients with type 2 diabetes mellitus (T2DM) remains limited. We evaluated the safety of LD withdrawal, utilizing multiparametric congestion monitoring, and factors associated with congestion development in such patients. Methods: Sixty ambulatory HF patients with T2DM were randomized to either continuation or withdrawal of LD, in our open-label pilot study. Participants underwent assessment for congestion (subclinical and clinical) using a multiparametric approach, including lung ultrasound, venous excess ultrasound, N-terminal pro–B-type natriuretic peptide (NT-proBNP), and six-minute walk test. Results: In this study, 35.0% of participants developed congestion (31.7% subclinical and 15.0% clinical). There were no significant differences for subclinical (36.7% vs 26.7%; p=0.405), clinical (20.0% vs 10.0%; p=0.278), or composite congestion (43.4% vs 26.7%; p=0.176) between both study arms. Abnormal hepatic vein Doppler patterns (possibly suggestive of subclinical congestion) were more frequent in the LD withdrawal arm (16.7% vs 0.0%; p=0.020). Elevated baseline NT-proBNP was independently associated with subclinical (odds ratio [OR] 1.448; p=0.008), clinical (OR 1.737; p<0.001) and composite congestion (OR 1.480; p=0.015) in exploratory multivariable analyses. Conclusion: In this pilot open-label study, short-term loop diuretic withdrawal in carefully selected, clinically euvolemic ambulatory HF patients with T2DM, was feasible and not associated with a statistically significant excess of clinical or subclinical congestion over 4 weeks. These findings require confirmation in larger, adequately powered multicentre trials with longer follow-up and clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Shariff et al. (2026) conducted an RCT in Heart failure and type 2 diabetes mellitus (n=60). Loop diuretic withdrawal (cessation of oral frusemide) vs. Continuation of oral frusemide 40 mg daily was evaluated on Composite congestion (any clinical or subclinical congestion at 4 weeks) (p=0.176). Short-term loop diuretic withdrawal did not increase composite congestion compared to continuation in euvolemic patients with heart failure and type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: